title: Differential characteristics of CD133(+) and CD133 (-) Jurkat cells.
abstract: T cell acute lymphoblastic leukemia (T-ALL) is a hematological disease including malignancy of T cell precursors. There are some T-ALL patients that are drug-resistant. A major cause of treatment failure in cancers can be associated with the existence of cancer stem cells. The identification of these cell populations helps us to clarify resistance mechanisms and rely on special markers for recognizing cancer stem cells. CD133 is one of the markers that is used for the identification of cancer stem cells. In this study, we evaluated CD133(+) and CD133(-) characteristic cells in Jurkat cells by assay proliferation, invasion, and apoptosis. CD133(+) and CD133(-) Jurkat cells were separated and immediately analyzed for proliferation, invasion, and doxorubicin-induced apoptosis. Proliferation, invasion, and resistance to chemotherapy of CD133(+) Jurkat cells were significantly more than CD133(-) Jurkat cells. Also, our results showed that CD133(+) Jurkat cells expressed ABCG2 gene more than CD133(-) Jurkat cells. In conclusion, CD133 marker could be introduced as a specific marker of cancer stem cells in Jurkat cell line.
authors: Department of Hematology School of Medical Sciences, Tarbiat Modares University, P.O. Box 14115-331, Tehran, Iran.
authors: Azadeh
authors: A
authors: Anbarlou
authors: Amir
authors: A
authors: Atashi
authors: Masoud
authors: M
authors: Soleimani
authors: Mahshid
authors: M
authors: AkhavanRahnama
authors: Mahbobeh
authors: M
authors: Bohloli
authors: Majid
authors: M
authors: Mossahebi-Mohammadi
mesh_terms: D000071916:AC133 Antigen; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters / Q000378:metabolism; D017304:Annexin A5 / Q000378:metabolism; D015703:Antigens, CD / Q000378:metabolism*; D017209:Apoptosis; D014408:Biomarkers, Tumor / Q000378:metabolism; D005434:Flow Cytometry; D016650:Fluorescein-5-isothiocyanate / Q000378:metabolism; D006023:Glycoproteins / Q000378:metabolism*; D006801:Humans; D019169:Jurkat Cells; D009363:Neoplasm Proteins / Q000378:metabolism; D014411:Neoplastic Stem Cells / Q000378:metabolism; D010455:Peptides / Q000378:metabolism*; D060888:Real-Time Polymerase Chain Reaction
chemical_list: C116614:ABCG2 protein, human; D000071916:AC133 Antigen; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters; D017304:Annexin A5; D015703:Antigens, CD; D014408:Biomarkers, Tumor; D006023:Glycoproteins; D009363:Neoplasm Proteins; C000606023:PROM1 protein, human; D010455:Peptides; D016650:Fluorescein-5-isothiocyanate
references: Cancer Cell. 2012 Mar 20;21(3):283-96
references: 22439924
references: Trends Mol Med. 2008 Oct;14(10):450-60
references: 18775674
references: Cancer Cell. 2002 Feb;1(1):75-87
references: 12086890
references: Lancet. 2008 Mar 22;371(9617):1030-43
references: 18358930
references: Nat Rev Immunol. 2004 Apr;4(4):301-8
references: 15057788
references: Nat Med. 2011 Mar;17(3):313-9
references: 21386835
references: Cancer Res. 2008 Dec 1;68(23 ):9703-11
references: 19047148
references: J Clin Oncol. 2008 Mar 20;26(9):1496-503
references: 18349402
references: Cancer Res. 2005 May 15;65(10 ):4320-33
references: 15899824
references: Biochem Biophys Res Commun. 2007 Apr 20;355(4):855-9
references: 17307142
references: Biochem Biophys Res Commun. 2006 Dec 29;351(4):820-4
references: 17097610
references: Eur J Cancer. 2007 Mar;43(5):935-46
references: 17320377
references: Am J Pathol. 2013 Feb;182(2):565-76
references: 23195431
references: Biochem Pharmacol. 2003 Oct 1;66(7):1207-18
references: 14505800
references: Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6
references: 16488983
references: Biochem Biophys Res Commun. 2008 Sep 5;373(4):567-71
references: 18590703
references: Nature. 2001 Nov 1;414(6859):105-11
references: 11689955
references: PLoS One. 2008;3(10 ):e3469
references: 18941626
references: Stem Cells Dev. 2009 Oct;18(8):1127-34
references: 19409053
references: Cancer Invest. 2009 Oct;27(8):844-50
references: 19626493
references: PLoS One. 2008 Jul 09;3(7):e2637
references: 18612434
references: Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33
references: 15381773